{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:57:44Z","timestamp":1787068664924,"version":"build-2736575974"},"reference-count":21,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Radiation recall dermatitis (RRD) following immune checkpoint inhibitor (ICI) therapy has been infrequently reported. Case Presentation: We present a 47-year-old female patient who developed RRD of the breast following three doses of pembrolizumab administered as an adjuvant treatment post-nephrectomy for Stage III renal cell carcinoma (RCC). Notably, the affected breast had previously undergone external beam radiotherapy 247 weeks earlier for Stage IA invasive ductal carcinoma. She had received no prior chemotherapy at any point. RRD manifested as breast induration, erythema, and peau d\u2019orange, and contraction of breast volume was noted following three cycles of pembrolizumab on week 17 (400 mg dose every 6 weeks). The dermatitis responded rapidly to systemic corticosteroids and no treatment interruption was needed. Conclusions: To date, this is the longest reported interval from completion of radiotherapy to RRD. A literature search underscores the variability in presentation and management of ICI-associated RRD.<\/jats:p>","DOI":"10.3390\/reports7040091","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T06:30:48Z","timestamp":1730788248000},"page":"91","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy"],"prefix":"10.3390","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3946-7247","authenticated-orcid":false,"given":"Caroline J.","family":"Cushman","sequence":"first","affiliation":[{"name":"Department of Medicine, Texas Tech University Health Science Center, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuad","family":"Abaleka","sequence":"additional","affiliation":[{"name":"Department of Medicine, Covenant Health, Lubbock, TX 79410, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3035-8014","authenticated-orcid":false,"given":"Andrew F.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Texas Tech University Health Science Center, Lubbock, TX 79430, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Yalamanchili","sequence":"additional","affiliation":[{"name":"Department of Medicine, Covenant Health, Lubbock, TX 79410, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seshadri","family":"Thirumala","sequence":"additional","affiliation":[{"name":"Department of Pathology, Covenant Health, Lubbock, TX 79410, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Quick","sequence":"additional","affiliation":[{"name":"Department of Medicine, Texas Tech University Health Science Center, Lubbock, TX 79430, USA"},{"name":"Department of Medicine, Covenant Health, Lubbock, TX 79410, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-8140(01)00328-0","article-title":"Characterizing the phenomenon of radiation recall dermatitis","volume":"59","author":"Camidge","year":"2001","journal-title":"Radiother. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1053\/j.seminoncol.2022.04.001","article-title":"Radiation recall dermatitis: A review of the literature","volume":"49","author":"Bhangoo","year":"2022","journal-title":"Semin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.ejca.2012.12.009","article-title":"Targeted therapy-induced radiation recall","volume":"49","author":"Levy","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00066-016-0950-7","article-title":"Radiation recall dermatitis induced by sorafenib: A case study and review of the literature","volume":"192","author":"Stieb","year":"2016","journal-title":"Strahlenther. Onkol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.radonc.2020.09.037","article-title":"Can radiation-recall predict long lasting response to immune checkpoint inhibitors?","volume":"154","author":"Deutsch","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"FSO378","DOI":"10.2144\/fsoa-2018-0123","article-title":"Radiation recall pneumonitis in the setting of immunotherapy and radiation: A focused review","volume":"5","author":"McGovern","year":"2019","journal-title":"Futur. Sci. OA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s40425-019-0803-x","article-title":"Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: A case report and review of the literature","volume":"7","author":"Carausu","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_11","first-page":"e15548","article-title":"Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review","volume":"13","author":"Yigit","year":"2021","journal-title":"Cureus"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/imt-2019-0020","article-title":"Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: A case report","volume":"12","author":"Billena","year":"2020","journal-title":"Immunotherapy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.jtho.2020.05.014","article-title":"Concomitant Radiation Recall Dermatitis and Radiation Recall Pneumonitis Induced by Pembrolizumab","volume":"15","author":"Wang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e14417","DOI":"10.1111\/dth.14417","article-title":"Radiation recall during cemiplimab therapy for locally adanced cutaneous squamous cell carcinoma","volume":"33","author":"Vaccaro","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"23247096231168114","DOI":"10.1177\/23247096231168114","article-title":"Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature","volume":"11","author":"Sandhu","year":"2023","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"101239","DOI":"10.1016\/j.gore.2023.101239","article-title":"Radiation recall dermatitis during treatment of endometrial cancer with pembrolizumab plus lenvatinib: A case report","volume":"48","author":"Heisler","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Teng, F., Li, M., and Yu, J. (2020). Radiation recall pneumonitis induced by PD-1\/PD-L1 blockades: Mechanisms and therapeutic implications. BMC Med., 18.","DOI":"10.1186\/s12916-020-01718-3"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/0378-6323.174422","article-title":"The immunocompromised cutaneous district and the necessity of a new classification of its disparate causes","volume":"82","author":"Caccavale","year":"2016","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cosio, T., Coniglione, F., Flaminio, V., Gaziano, R., Coletta, D., Petruccelli, R., Dika, E., Bianchi, L., and Campione, E. (2023). Pyodermitis during Nivolumab Treatment for Non-Small Cell Lung Cancer: A Case Report and Review of the Literature. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054580"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Alotaibi, F.M., Min, W.-P., and Koropatnick, J. (2024). CD5 blockade, a novel immune checkpoint inhibitor, enhances T cell anti-tumour immunity and delays tumour growth in mice harbouring poorly immunogenic 4T1 breast tumour homografts. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1256766"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e96101","DOI":"10.1172\/jci.insight.96101","article-title":"A type of human skin dendritic cell marked by CD5 is associated with the development of inflammatory skin disease","volume":"2","author":"Korenfeld","year":"2017","journal-title":"JCI Insight"}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/7\/4\/91\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:28:03Z","timestamp":1760113683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/7\/4\/91"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["reports7040091"],"URL":"https:\/\/doi.org\/10.3390\/reports7040091","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]}}}